-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Creating an Optimal Strategy for Lipid Management

Dialogue: Implementation of Guidelines in a Managed Care Setting

By

December 1st 1996

Dialogue: The Lipid-Lowering Formulary

By

December 1st 1996

Case Study B

ByDonald B. Hunninghake, MD,MyNgoc A. Dang, PharmD,Larry Goodnight, RPh,Dean Inami, PharmD,Sheryl Sun, MD,Mohan Vodoor, RPh

December 1st 1996

Case Study C

ByRobert Jacobs, MD,Tom J. Davies, JD, MPA,Cindy Giambrone, PharmD,Lionel Graveline, RPh,Robert Jastrzab, RPh,Daniel H. Lewis, RPh, MBA

December 1st 1996

Case Study D

ByDavid Rutledge, PharmD,Chad Green, PharmD,Jennifer Mason, RN,Ramie Ramirez, RPh,Dan Steiber, RPh,Alan Wright, MD, MPH

December 1st 1996

Goals and Objectives

By

December 1st 1996

Introduction: Creating an Optimal Strategy for Lipid Management

ByJames M. McKenney, PharmD,William H. Frishman, MD

December 1st 1996

Recent Clinical Trials and Aggressive Management of Dyslipidemic Patients

ByDonald B. Hunninghake, MD

December 1st 1996

Epidemiologic Studies of Diet and Drug Therapy to Reach Target LDL-C Levels

ByErza A. Amsterdam, MD

December 1st 1996

Implementation of Guidelines in a Managed Care Setting

ByMarcus Wilson, PharmD

December 1st 1996

The Lipid-Lowering Formulary

ByJames M. McKeney, PharmD

December 1st 1996

Case Study A

ByAnne C. Goldberg, MD,Herb Bobo, RPh,Ken Kellick, PharmD,Andrew Szczotka, PharmD

December 1st 1996

Selected Abstracts

By

December 1st 1996

CME Quiz

By

December 1st 1996

Bibliography

By

December 1st 1996

Participants

By

December 1st 1996

Dialogue: Recent Clinical Trials and Aggressive Management of Dyslipidemic Patients

By

December 1st 1996

Dialogue: Epidemiologic Studies of Diet and Drug Therapy to Reach Target LDL-C Levels

By

December 1st 1996

Trending on AJMC

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned